Clinical Characteristics of HLA-B27-Associated Anterior Uveitis in a Finnish Population-Based Cohort
Leino, Aada; Pesälä, Roosa; Siiskonen, Mira; Ohtonen, Pasi; Hautala, Nina (2024-06-06)
Taylor & Francis
06.06.2024
Leino, A., Pesälä, R., Siiskonen, M., Ohtonen, P., & Hautala, N. (2024). Clinical Characteristics of HLA-B27-Associated Anterior Uveitis in a Finnish Population-Based Cohort. Ocular Immunology and Inflammation, 33(1), 98–104. https://doi.org/10.1080/09273948.2024.2360593
https://creativecommons.org/licenses/by-nc/4.0/
Copyright © 2025 Informa UK Limited. This is an Accepted Manuscript version of the following article, accepted for publication in Ocular Immunology and Inflammation. Leino, A., Pesälä, R., Siiskonen, M., Ohtonen, P., & Hautala, N. (2024). Clinical Characteristics of HLA-B27-Associated Anterior Uveitis in a Finnish Population-Based Cohort. Ocular Immunology and Inflammation, 33(1), 98–104. It is deposited under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
https://creativecommons.org/licenses/by-nc/4.0/
Copyright © 2025 Informa UK Limited. This is an Accepted Manuscript version of the following article, accepted for publication in Ocular Immunology and Inflammation. Leino, A., Pesälä, R., Siiskonen, M., Ohtonen, P., & Hautala, N. (2024). Clinical Characteristics of HLA-B27-Associated Anterior Uveitis in a Finnish Population-Based Cohort. Ocular Immunology and Inflammation, 33(1), 98–104. It is deposited under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
https://creativecommons.org/licenses/by-nc/4.0/
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:oulu-202505143411
https://urn.fi/URN:NBN:fi:oulu-202505143411
Tiivistelmä
Abstract
Purpose:
To evaluate the clinical characteristics, treatment outcomes and ocular complications in patients with HLA-B27-associated AU compared to those without HLA-B27.
Methods:
From the population-based data of all adult patients with AU during 2009–2020 (n = 413), 241 patients tested for HLA-B27 were included. Age of the initial onset, gender, etiology, course of uveitis, visual outcomes and complications were studied.
Results:
170 patients (71%) were HLA-B27+ and 71 (29%) HLA-B27-. Mean age at uveitis onset was 37 ± 13 in HLA-B27+ (95% CI, 35.4–39.3) and 43 ± 14 (95% CI, 40.3–46.4) in HLA-B27- patients (p = 0.001). Male:female ratio was 1.1:1 among HLA-B27+ and 0.58:1 (p = 0.024) in HLA-B27- patients. Most patients, 63% in HLA-B27+ and 68% in HLA-B27- had chronic uveitis. Recurrences were noted in 31% in HLA-B27+ group compared to 13%in HLA-B27-. 51% and 17% of HLA-B27+ and HLA-B27- patients, respectively, had systemic disease-associated uveitis. Etiology was Idiopathic in 44% and 69% of HLA-B27+ and HLA-B27- patients, respectively (p < 0.001). After the follow-up, +2 and −4 ETDRS letters changes were noted in HLA-B27+ and HLA-B27- patients (p = 0.005). Ocular complications developed in 43% and 47%, and surgical treatment of complications was required in 20% and 33% of patients in HLA-B27+ and HLA-B27- patients (p = 0.009). 1% (HLA-B27+) and 3% (HLA-B27-) developed visual impairment.
Conclusion:
Our results highlight the differences in the age of uveitis onset, gender distribution, course of uveitis, etiology, and treatment outcomes in HLA-B27+ and HLA-B27-uveitis. HLA-B27 seems to be associated with younger age at uveitis onset, more recurrences, systemic diseases, and better treatment outcomes with less complications.
Purpose:
To evaluate the clinical characteristics, treatment outcomes and ocular complications in patients with HLA-B27-associated AU compared to those without HLA-B27.
Methods:
From the population-based data of all adult patients with AU during 2009–2020 (n = 413), 241 patients tested for HLA-B27 were included. Age of the initial onset, gender, etiology, course of uveitis, visual outcomes and complications were studied.
Results:
170 patients (71%) were HLA-B27+ and 71 (29%) HLA-B27-. Mean age at uveitis onset was 37 ± 13 in HLA-B27+ (95% CI, 35.4–39.3) and 43 ± 14 (95% CI, 40.3–46.4) in HLA-B27- patients (p = 0.001). Male:female ratio was 1.1:1 among HLA-B27+ and 0.58:1 (p = 0.024) in HLA-B27- patients. Most patients, 63% in HLA-B27+ and 68% in HLA-B27- had chronic uveitis. Recurrences were noted in 31% in HLA-B27+ group compared to 13%in HLA-B27-. 51% and 17% of HLA-B27+ and HLA-B27- patients, respectively, had systemic disease-associated uveitis. Etiology was Idiopathic in 44% and 69% of HLA-B27+ and HLA-B27- patients, respectively (p < 0.001). After the follow-up, +2 and −4 ETDRS letters changes were noted in HLA-B27+ and HLA-B27- patients (p = 0.005). Ocular complications developed in 43% and 47%, and surgical treatment of complications was required in 20% and 33% of patients in HLA-B27+ and HLA-B27- patients (p = 0.009). 1% (HLA-B27+) and 3% (HLA-B27-) developed visual impairment.
Conclusion:
Our results highlight the differences in the age of uveitis onset, gender distribution, course of uveitis, etiology, and treatment outcomes in HLA-B27+ and HLA-B27-uveitis. HLA-B27 seems to be associated with younger age at uveitis onset, more recurrences, systemic diseases, and better treatment outcomes with less complications.
Kokoelmat
- Avoin saatavuus [38549]
Ellei muuten mainita, aineiston lisenssi on https://creativecommons.org/licenses/by-nc/4.0/